Edition:
United States

Bristol-Myers Squibb Co (BMY)

BMY on New York Consolidated

55.77USD
23 Feb 2017
Change (% chg)

$0.42 (+0.76%)
Prev Close
$55.35
Open
$55.63
Day's High
$56.09
Day's Low
$55.02
Volume
14,410,368
Avg. Vol
12,385,237
52-wk High
$77.12
52-wk Low
$46.01

Latest Key Developments (Source: Significant Developments)

Bristol-Myers Squibb prices $1.5 billion of senior notes
Wednesday, 22 Feb 2017 06:00pm EST 

Bristol-myers Squibb Co :Bristol-Myers Squibb prices $1.5 billion of senior notes.  Full Article

Bristol-Myers sees restructuring charges between $1.5-$2.0 bln through 2020
Tuesday, 21 Feb 2017 12:23pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb says expects to incur charges through 2020, ranging between $1.5 billion to $2.0 billion in connection with restructuring announced in Oct 2016 . Bristol-Myers Squibb - Cash outlays in connection with the actions expected to be about 40% to 50% of the total charges .Bristol-Myers Squibb - Charges of about $90 million recognized during Q4, primarily from certain research and development employee workforce reductions and accelerated depreciation on expected early site exits.  Full Article

Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab)
Thursday, 2 Feb 2017 04:15pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer .Bristol-Myers Squibb receives FDA approval for Opdivo (Nivolumab) in previously treated locally advanced or metastatic urothelial carcinoma, a type of bladder cancer.  Full Article

FDA grants accelerated approval to Bristol-Myers Squibb's nivolumab
Thursday, 2 Feb 2017 02:33pm EST 

U.S. Food and Drug Administration:Granted accelerated approval to Bristol-Myers Squibb Company's nivolumab for treatment of locally advanced or metastatic urothelial carcinoma.  Full Article

Bristol-Myers squibb announces European Patent Office decision on Sprycel
Wednesday, 1 Feb 2017 12:19pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb announces European Patent Office decision on Sprycel . Bristol-Myers Squibb Co says decision does not impact patents outside of EU or other Sprycel -related patents .Bristol-Myers squibb co says EPO upheld a decision that found patent to be invalid.  Full Article

Bristol-Myers Squibb reports Q4 non-GAAP earnings per share of $0.63
Thursday, 26 Jan 2017 06:59am EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb reports fourth quarter and full year 2016 financial results . Q4 non-GAAP earnings per share $0.63 . Q4 earnings per share $0.53 . Q4 earnings per share view $0.67 -- Thomson Reuters I/B/E/S . Q4 revenue $5.2 billion versus I/B/E/S view $5.12 billion . Bristol-Myers Squibb says adjusts FY 2017 non-GAAP earnings per share outlook to $2.70 to $2.90 . Reaffirms FY 2017 GAAP earnings per share view $2.47 to $2.67 . Confirms 2017 GAAP eps guidance range of $2.47 to $2.67 and adjusts non-GAAP eps guidance range to $2.70 to $2.90 . Sees 2017 worldwide revenues increasing in low-single digits . Qtrly yervoy worldwide revenue $264 million versus $265 million . Sees 2017 gross margin as a percentage of revenue to be approximately 72% to 73% for both GAAP and non-GAAP . qtrly eliquis worldwide revenue $948 million versus $602 million . Q4 opdivo worldwide revenues $1,310 million versus $475 million last year . Q4 sprycel worldwide revenues $494 million versus $429 million last year . FY2017 earnings per share view $2.96 -- Thomson Reuters I/B/E/S .Sees 2017 research and development expenses increasing in high-single digit range for both GAAP and non-GAAP.  Full Article

Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck
Friday, 20 Jan 2017 04:01pm EST 

Bristol-myers Squibb Co - : Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with merck to resolve PD-1 antibody patent litigation . Merck to pay Bristol-Myers Squibb and Ono royalties on global sales of keytruda through 2026, and lump-sum payment of $625 million . Agreement will result in dismissal with prejudice of all patent litigation between companies pertaining to keytruda . Agreement ends all global patent-infringement litigation against Merck's sale of keytruda . Merck is also obligated to pay ongoing royalties on global sales of keytruda of 6.5% from Jan 1, 2017 through Dec 31, 2023 . Companies have also granted certain rights to each other under their respective patent portfolios pertaining to PD-1 . Merck is also obligated to pay ongoing royalties on global sales of keytruda 2.5% from January 1, 2024 through Dec 31, 2026 . Royalties pertaining to PD-1 to be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively .Royalties will be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively.  Full Article

Merck announces license agreement resolving Keytruda patent litigation
Friday, 20 Jan 2017 04:01pm EST 

Merck & Co Inc - : Merck announces settlement and license agreement resolving Keytruda® (pembrolizumab) patent litigation . Under settlement and license agreement, company will make a one-time payment of $625 million to Bristol-Myers Squibb . Parties also agreed to dismiss all claims in relevant legal proceedings . $625 million payment will be recorded in company's fourth-quarter and full-year 2016 results . The expense will be excluded from merck's non-gaap results .Parties also agreed to dismiss all claims in relevant legal proceedings..  Full Article

Bristol-Myers sees operating expenses flat through 2020
Tuesday, 10 Jan 2017 12:55pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb CEO says expects oncology portfolio to be impacted by competition in 2017, particularly in lung cancer . Bristol-Myers sees potential for pivotal data from 14 trials in 10 tumor types over next 24 months . Bristol-Myers sees operating expenses remaining at 2016 level of about $9 billion through 2020 .Bristol-Myers CEO says business development remains key component of research and development strategy - JP Morgan Healthcare Conference.  Full Article

Bristol-Myers, Calithera Biosciences collaborate to test opdivo along with CB-839
Wednesday, 21 Dec 2016 06:59am EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb and Calithera Biosciences announce clinical collaboration to evaluate opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma .Bristol-Myers Squibb Co says study to evaluate potential of CB-839 plus opdivo to target immune-suppressive cells in tumor microenvironment.  Full Article

More From Around the Web

BRIEF-Bristol-Myers Squibb prices $1.5 billion of senior notes

* Bristol-Myers Squibb prices $1.5 billion of senior notes Source text for Eikon: Further company coverage: